| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615380 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 21 Pages |
Abstract
In real life, ponatinib is a “niche-drug” reserved for a unique population of exceptionally young patients with CML with or without the T315I mutation. In this highly selected group, very different from the PACE cohort, ponatinib achieved high overall response rates.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Adi Shacham-Abulafia, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, Ilana Helman, Liat Shargian, Anna Gourevitch, Evgeni Chubar, Roy Ratzon, Uri Rozovski,